Abbvie Stock News

Balasa Dinverno & Foltz LLC lowered its stake in AbbVie Inc. (NYSE:ABBV) by 2.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 29,036 shares of the companys stock after selling 855 shares during the quarter. Balasa Dinverno & Foltz LLCs holdings []

Vuity, a new eye drop from AbbVie company Allergan, can improve near vision for up to six hours after application.

Related Stocks: ABBV ,

Traynor Capital Management Inc. lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 11.1% in the third quarter, according to its most recent filing with the SEC. The firm owned 4,260 shares of the companys stock after acquiring an additional 426 shares during the period. Traynor Capital Management Inc.s holdings in AbbVie were worth []

Disclosing Tablets Market Forecast to 2028 - COVID-19 Impact and Global Analysis The component of a drug that produces the desired effects is known as the active pharmaceutical ingredient (API). Combination therapies, for example, in long term treatments have various active

Capital Advisors Inc. OK raised its stake in AbbVie Inc. (NYSE:ABBV) by 0.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 322,901 shares of the companys stock after acquiring an additional 1,086 shares during the period. AbbVie accounts for about 1.0% []

DUBLIN--(BUSINESS WIRE)--The "Global Multiple Sclerosis Drugs Market 2020-2027" report has been added to ResearchAndMarkets.com''s offering. The global multiple sclerosis drugs market will reach $29.97 billion by 2027, growing by 4.3% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. The report is based on a comprehensive research of the entire global multiple sclero

OLD National Bancorp IN increased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 3.4% in the 3rd quarter, Holdings Channel.com reports. The firm owned 126,303 shares of the companys stock after purchasing an additional 4,187 shares during the period. OLD National Bancorp INs holdings in AbbVie were worth $13,624,000 as of its most recent []

DUBLIN--(BUSINESS WIRE)--The "Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global adalimumab, infliximab and etanercept biosimilars market is expected to grow from $2.21 billion in 2020 to $3.02 billion in 2021 at a compound annual growth rate (CAGR) of 36.7%. The market is expected to reach $12.2 billion in 2025 at a CAGR of 42%. Major players in the adalimumab, i

Seventh Clinical Collaboration Represents Continued Execution on Strategy to Advance Nirogacestat in Combination with BCMA Therapies

This Antibodies market report provides a comprehensive review of the key aspects that will drive market growth, including market drivers, constraints, and opportunities, challenges, current trends, and technical breakthroughs. This Antibodies market report includes industry analysis, growth development, and current

Industrial Growth Forecast Report Cystic Fibrosis Market 2021-2028: The Market Report provides Insightful information to the clients enhancing their basic leadership capacity identified with the Cystic Fibrosis Market business, including market dynamics, segmentation, competition, and regional growth. The strategy of

Sumitomo Life Insurance Co. lowered its stake in AbbVie Inc. (NYSE:ABBV) by 4.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,447 shares of the companys stock after selling 1,414 shares during the period. Sumitomo Life Insurance Co.s holdings in []

WASHINGTON (dpa-AFX) - Allergan, an AbbVie (ABBV) company, announced Thursday that VUITY (pilocarpine HCl ophthalmic solution) 1.25%, the first and only eye drop approved by the U.S. Food and Drug…